Bioventus Inc Cl A (BVS) Stock Price, Quote & News

Company Profile

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted...

Industry: Medical Devices

Sector: Healthcare

Phone: 919 474 6700

Website: www.bioventus.com

Address:

4721 Emperor Boulevard, Suite 100, Durham, United States

CosmicMiner Jul. 13 at 12:54 PM

MA flips are the cleanest setups in this market. We are sitting on major inflection points right now: $CDE / $ASAN / EVO: All flipping the 200DMA into solid support. $RXRX: 50WMA holding like a brick wall. $BVS: Looking prime here. $LEGN: Textbook retest of the 200DMA. Every single chart with precise entry and exit targets has been uploaded to my profile.

0 · Reply

Valuebuilder Jul. 13 at 9:58 AM

$BVS take a look at what Avanos got bought at.Bioventus generates more profit and is a far better company.There is big value here!

0 · Reply

Yqav Jul. 8 at 3:55 PM

$BVS holy cap and handle breaakout on the weekly chart. This stock has much more in it

0 · Reply

GordonGordon Jul. 8 at 3:52 PM

$BVS I keep thinking about the 15,000 calls people bought the other day....

0 · Reply

GordonGordon Jul. 8 at 3:52 PM

$BVS This is acting really well on a terrible day for the market!

0 · Reply

Spicy_Trade Jul. 7 at 12:59 AM

Bioventus Inc. ( $BVS ) SpicyTrade - Daily Stock Analysis https://youtu.be/ihhMPbQwROg?si=XTWgIGPqX130VrxK

0 · Reply

BreakoutLife Jul. 6 at 10:36 PM

$BVS showing strong breakout momentum, up another 12% today and poking just above key trendline resistance. Structurally, looking for a clean technical retest of this level to confirm the move. The macro wedge structure maps out a potential +69% gain to the top of the range.

0 · Reply

GordonGordon Jul. 6 at 7:32 PM

$BVS 14,500 of the $12.50 calls have traded. Wow.

0 · Reply

kshonstocks Jul. 6 at 3:10 PM

$BVS Bioventus shares rise after Medicare reverses reimbursement cuts

0 · Reply

GordonGordon Jul. 6 at 2:45 PM

$BVS wow

0 · Reply

Did Bioventus Inc. Insiders Breach their Fiduciary Duties to Shareholders?

2026-06-16T20:08:51.000Z - 4 weeks ago

Bioventus management to meet with Barrington

Jun 8, 2026, 4:00 PM EDT - 5 weeks ago

Bioventus Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 3, 2026, 10:00 AM EDT - 6 weeks ago

Bioventus Transcript: AGM 2026

Jun 2, 2026, 7:00 AM EDT - 6 weeks ago

Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference

2026-05-07T06:30:12.000Z - 2 months ago

Bioventus reports Q1 EPS 15c, consensus 7c

2026-05-07T06:26:59.000Z - 2 months ago

Bioventus raises FY26 adjusted EPS view to 75c-79c from 73c-77c

May 6, 2026, 8:30 AM EDT - 2 months ago

Bioventus Earnings Call Transcript: Q1 2026

May 6, 2026, 8:30 AM EDT - 2 months ago

Bioventus Earnings release: Q1 2026

May 6, 2026, 8:30 AM EDT - 2 months ago

Bioventus Quarterly report: Q1 2026

May 6, 2026, 8:30 AM EDT - 2 months ago

Bioventus Slides: Q1 2026

May 6, 2026, 7:30 AM EDT - 2 months ago

Bioventus Reports First Quarter Financial Results

Apr 28, 2026, 4:15 PM EDT - 2 months ago

Bioventus to Report First Quarter of Fiscal Year 2026 Financial Results on May 6, 2026

Apr 22, 2026, 8:00 AM EDT - 3 months ago

Bioventus Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 3 months ago

Bioventus Proxy statement: Proxy filing

2026-03-27T13:00:51.000Z - 3 months ago

Bioventus initiated with an Outperform at CJS Securities

Mar 16, 2026, 7:00 AM EDT - 4 months ago

Bioventus Slides: Corporate presentation

2026-03-09T18:55:09.000Z - 4 months ago

Bioventus management to meet with Barrington

2026-03-06T14:05:43.000Z - 4 months ago

Bioventus price target raised to $16 from $15 at Craig-Hallum

2026-03-06T12:35:37.000Z - 4 months ago

Bioventus price target raised to $14 from $13 at Barrington

Mar 5, 2026, 8:30 AM EST - 4 months ago

Bioventus Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:30 AM EST - 4 months ago

Bioventus Annual report: Q4 2025

Mar 5, 2026, 8:30 AM EST - 4 months ago

Bioventus Earnings release: Q4 2025

Mar 5, 2026, 8:30 AM EST - 4 months ago

Bioventus Slides: Q4 2025

2026-03-05T12:21:28.000Z - 4 months ago

Bioventus sees FY26 adjusted EPS 73c-77c, consensus 77c

2026-03-05T12:13:21.000Z - 4 months ago

Bioventus reports Q4 EPS 24c, consensus 22c

Mar 5, 2026, 7:00 AM EST - 4 months ago

Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results

Feb 24, 2026, 4:15 PM EST - 5 months ago

Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026

2026-02-09T13:00:47.000Z - 5 months ago

Bioventus initiated with an Outperform at Barrington

Jan 14, 2026, 12:45 PM EST - 6 months ago

Bioventus Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 12:45 PM EST - 6 months ago

Bioventus Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 7:30 AM EST - 6 months ago

Bioventus to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 5, 2025, 3:30 PM EST - 7 months ago

HALPER SADEH LLC ENCOURAGES BIOVENTUS INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Dec 3, 2025, 10:10 AM EST - 8 months ago

Bioventus Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 10:10 AM EST - 8 months ago

Bioventus Slides: Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 4:15 PM EST - 8 months ago

Bioventus to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 4, 2025, 8:30 AM EST - 9 months ago

Bioventus Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:30 AM EST - 9 months ago

Bioventus Quarterly report: Q3 2025

Nov 4, 2025, 8:30 AM EST - 9 months ago

Bioventus Earnings release: Q3 2025

Nov 4, 2025, 8:30 AM EST - 9 months ago

Bioventus Slides: Q3 2025

2025-11-04T12:41:02.000Z - 9 months ago

Bioventus reports Q3 EPS 15c vs 5c last year

2025-11-04T12:40:38.000Z - 9 months ago

Bioventus sees FY25 EPS 64c-68c

Nov 4, 2025, 7:30 AM EST - 9 months ago

Bioventus Reports Third Quarter Financial Results

Oct 28, 2025, 7:00 AM EDT - 9 months ago

Bioventus to Report Third Quarter of Fiscal Year 2025 Financial Results on November 4, 2025

Oct 22, 2025, 7:08 PM EDT - 9 months ago

Halper Sadeh LLC Encourages Bioventus Inc. Shareholders to Contact the Firm to Discuss Their Rights

Sep 10, 2025, 1:05 PM EDT - 10 months ago

Bioventus Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 7:30 AM EDT - 11 months ago

Bioventus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 12, 2025, 2:00 PM EDT - 1 year ago

Bioventus Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 12, 2025, 2:00 PM EDT - 1 year ago

Bioventus Slides: Canaccord Genuity’s 45th Annual Growth Conference

Aug 7, 2025, 4:15 PM EDT - 1 year ago

Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Bioventus Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Bioventus Quarterly report: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Bioventus Earnings release: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Bioventus Slides: Q2 2025

2025-08-06T11:15:44.000Z - 1 year ago

Bioventus reports Q2 EPS 21c, consensus 20c

2025-08-06T11:15:32.000Z - 1 year ago

Bioventus sees FY25 EPS 64c-68c, consensus 66c

Aug 6, 2025, 7:00 AM EDT - 1 year ago

Bioventus Reports Second Quarter Financial Results

2025-08-04T12:15:21.000Z - 1 year ago

Bioventus enters $400M senior secured credit agreement

Aug 4, 2025, 8:00 AM EDT - 1 year ago

Bioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased Liquidity

2025-07-30T11:41:34.000Z - 1 year ago

Bioventus receives FDA 510k clearances for two next-gen PNS products

Jul 30, 2025, 7:30 AM EDT - 1 year ago

Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products

Jul 29, 2025, 4:15 PM EDT - 1 year ago

Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025

2025-07-07T10:11:52.000Z - 1 year ago

Bioventus initiated with an Overweight at Cantor Fitzgerald

2025-06-18T19:30:34.000Z - 1 year ago

Bioventus management to meet with Craig-Hallum

2025-05-07T13:21:29.000Z - 1 year ago

Bioventus price target lowered to $15 from $17 at Craig-Hallum

May 6, 2025, 8:30 AM EDT - 1 year ago

Bioventus Earnings Call Transcript: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Bioventus Quarterly report: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Bioventus Earnings release: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Bioventus Slides: Q1 2025

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Bioventus Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Bioventus Proxy statement: Proxy Filing

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Bioventus Earnings Call Transcript: Q4 2024

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Bioventus Annual report: Q4 2024

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Bioventus Earnings release: Q4 2024

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Bioventus Slides: Q4 2024

Mar 11, 2025, 7:30 AM EDT - 1 year ago

Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results

Feb 28, 2025, 7:30 AM EST - 1 year ago

Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025

Jan 15, 2025, 1:30 PM EST - 1 year ago

Bioventus Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 1:30 PM EST - 1 year ago

Bioventus Slides: FY 2025

Jan 2, 2025, 8:00 AM EST - 1 year ago

Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners

Nov 5, 2024, 8:30 AM EST - 1 year ago

Bioventus Earnings Call Transcript: Q3 2024

Nov 5, 2024, 8:30 AM EST - 1 year ago

Bioventus Quarterly report: Q3 2024

Nov 5, 2024, 8:30 AM EST - 1 year ago

Bioventus Earnings release: Q3 2024

Nov 5, 2024, 8:30 AM EST - 1 year ago

Bioventus Slides: Q3 2024

Oct 29, 2024, 7:30 AM EDT - 1 year ago

Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024

Oct 25, 2024, 8:00 AM EDT - 1 year ago

Bioventus Registration statement: Registration Filing

Aug 14, 2024, 9:00 AM EDT - 2 years ago

Bioventus Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Aug 14, 2024, 9:00 AM EDT - 2 years ago

Bioventus Slides: FY 2024

Aug 7, 2024, 4:15 PM EDT - 2 years ago

Bioventus to Present at the Canaccord Genuity 44th Annual Global Growth Conference

Aug 6, 2024, 8:30 AM EDT - 2 years ago

Bioventus Earnings Call Transcript: Q2 2024

Aug 6, 2024, 8:30 AM EDT - 2 years ago

Bioventus Quarterly report: Q2 2024

Aug 6, 2024, 8:30 AM EDT - 2 years ago

Bioventus Earnings release: Q2 2024

Aug 6, 2024, 8:30 AM EDT - 2 years ago

Bioventus Slides: Q2 2024

Jul 30, 2024, 7:30 AM EDT - 2 years ago

Bioventus to Report Second Quarter of Fiscal Year 2024 Financial Results on August 6, 2024

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Bioventus Proxy statement: Proxy Filing

May 7, 2024, 8:30 AM EDT - 2 years ago

Bioventus Earnings Call Transcript: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

Bioventus Quarterly report: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

Bioventus Earnings release: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

Bioventus Slides: Q1 2024

Apr 29, 2024, 7:30 AM EDT - 2 years ago

Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Bioventus Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Bioventus Proxy statement: Proxy Filing

Apr 10, 2024, 8:00 AM EDT - 2 years ago

Bioventus Proxy statement: Proxy Filing

Mar 12, 2024, 8:30 AM EDT - 2 years ago

Bioventus Earnings Call Transcript: Q4 2023

Mar 12, 2024, 8:30 AM EDT - 2 years ago

Bioventus Annual report: Q4 2023

Mar 12, 2024, 8:30 AM EDT - 2 years ago

Bioventus Earnings release: Q4 2023

Mar 12, 2024, 8:30 AM EDT - 2 years ago

Bioventus Slides: Q4 2023

Mar 12, 2024, 7:30 AM EDT - 2 years ago

Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results

Mar 4, 2024, 8:00 AM EST - 2 years ago

Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024

Jan 18, 2024, 4:15 PM EST - 2 years ago

Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility

Jan 12, 2024, 4:15 PM EST - 2 years ago

Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole

Dec 19, 2023, 4:30 PM EST - 2 years ago

Bioventus Names Robert Claypoole as President and Chief Executive Officer

Dec 6, 2023, 8:00 AM EST - 2 years ago

Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis

Nov 7, 2023, 8:30 AM EST - 2 years ago

Bioventus Earnings Call Transcript: Q3 2023

Nov 7, 2023, 8:30 AM EST - 2 years ago

Bioventus Quarterly report: Q3 2023

Nov 7, 2023, 8:30 AM EST - 2 years ago

Bioventus Earnings release: Q3 2023

Nov 7, 2023, 8:30 AM EST - 2 years ago

Bioventus Slides: Q3 2023

Nov 7, 2023, 7:00 AM EST - 2 years ago

Bioventus Reports Third Quarter Financial Results; Raises Full Year 2023 Financial Guidance

Oct 31, 2023, 7:00 AM EDT - 2 years ago

Bioventus to Report Third Quarter of Fiscal Year 2023 Financial Results on November 7, 2023

Sep 19, 2023, 9:52 PM EDT - 3 years ago

Bioventus to Present at the Cantor Global Healthcare Conference

Sep 13, 2023, 8:50 AM EDT - 3 years ago

Bioventus Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Sep 6, 2023, 4:30 PM EDT - 3 years ago

Bioventus to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Aug 8, 2023, 8:30 AM EDT - 3 years ago

Bioventus Earnings Call Transcript: Q2 2023

Aug 8, 2023, 8:30 AM EDT - 3 years ago

Bioventus Quarterly report: Q2 2023

Aug 8, 2023, 8:30 AM EDT - 3 years ago

Bioventus Earnings release: Q2 2023

Aug 8, 2023, 8:30 AM EDT - 3 years ago

Bioventus Slides: Q2 2023

Aug 8, 2023, 7:30 AM EDT - 3 years ago

Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance

Aug 4, 2023, 8:30 AM EDT - 3 years ago

Bioventus to Present at the Canaccord Genuity 43rd Annual Global Growth Conference

Aug 1, 2023, 5:35 PM EDT - 3 years ago

Bioventus to Report Second Quarter of Fiscal Year 2023 Financial Results on August 8, 2023

May 23, 2023, 7:30 AM EDT - 3 years ago

Bioventus Completes Divestiture of its Wound Business

May 16, 2023, 5:00 PM EDT - 3 years ago

Bioventus Earnings Call Transcript: Q1 2023

May 16, 2023, 5:00 PM EDT - 3 years ago

Bioventus Quarterly report: Q1 2023

May 16, 2023, 5:00 PM EDT - 3 years ago

Bioventus Earnings release: Q1 2023

May 16, 2023, 5:00 PM EDT - 3 years ago

Bioventus Slides: Q1 2023

May 15, 2023, 5:33 PM EDT - 3 years ago

Bioventus Reschedules Reporting of First Quarter Fiscal Year 2023 Financial Results to After Market Close on May 16, 2023

May 11, 2023, 7:00 AM EDT - 3 years ago

Bioventus Reschedules Earnings Call to May 16, 2023; Files for Extension to File Form 10-Q for the Period Ended April 1, 2023

May 10, 2023, 9:00 AM EDT - 3 years ago

Bioventus Announces Divestiture of its Wound Business

May 3, 2023, 8:30 AM EDT - 3 years ago

Bioventus to Report First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023

Apr 27, 2023, 8:00 AM EDT - 3 years ago

Bioventus Proxy statement: Proxy Filing

Apr 27, 2023, 8:00 AM EDT - 3 years ago

Bioventus Proxy statement: Proxy Filing

Apr 5, 2023, 8:00 AM EDT - 3 years ago

Bioventus Announces CEO Leadership Change

Mar 31, 2023, 8:30 AM EDT - 3 years ago

Bioventus Earnings Call Transcript: Q4 2022

Mar 31, 2023, 8:30 AM EDT - 3 years ago

Bioventus Annual report: Q4 2022

Mar 31, 2023, 8:30 AM EDT - 3 years ago

Bioventus Earnings release: Q4 2022

Mar 31, 2023, 8:30 AM EDT - 3 years ago

Bioventus Slides: Q4 2022

Mar 31, 2023, 7:30 AM EDT - 3 years ago

Bioventus Reports Fourth Quarter and Full-Year 2022 Financial Results

Mar 29, 2023, 8:55 AM EDT - 3 years ago

Bioventus Reschedules Reporting of Fourth Quarter Fiscal Year 2022 Financial Results to March 31, 2023

Mar 16, 2023, 8:30 AM EDT - 3 years ago

Bioventus to Report Fourth Quarter of Fiscal Year 2022 Financial Results on March 30, 2023

CosmicMiner Jul. 13 at 12:54 PM

0 · Reply

Valuebuilder Jul. 13 at 9:58 AM

$BVS take a look at what Avanos got bought at.Bioventus generates more profit and is a far better company.There is big value here!

0 · Reply

Yqav Jul. 8 at 3:55 PM

$BVS holy cap and handle breaakout on the weekly chart. This stock has much more in it

0 · Reply

GordonGordon Jul. 8 at 3:52 PM

$BVS I keep thinking about the 15,000 calls people bought the other day....

0 · Reply

GordonGordon Jul. 8 at 3:52 PM

$BVS This is acting really well on a terrible day for the market!

0 · Reply

Spicy_Trade Jul. 7 at 12:59 AM

Bioventus Inc. ( $BVS ) SpicyTrade - Daily Stock Analysis https://youtu.be/ihhMPbQwROg?si=XTWgIGPqX130VrxK

0 · Reply

BreakoutLife Jul. 6 at 10:36 PM

0 · Reply

GordonGordon Jul. 6 at 7:32 PM

$BVS 14,500 of the $12.50 calls have traded. Wow.

0 · Reply

kshonstocks Jul. 6 at 3:10 PM

$BVS Bioventus shares rise after Medicare reverses reimbursement cuts

0 · Reply

GordonGordon Jul. 6 at 2:45 PM

$BVS wow

0 · Reply

ApexEquityVault Jul. 6 at 2:44 PM

500% POTENTIAL 💡 $BVS 12.5 Call 7/17 at 0.25

0 · Reply

LUXtrades0 Jul. 6 at 2:44 PM

$BVS 12.5 Call 7/17 at 0.25 🚨 TRUST ‼️

0 · Reply

ApexEquityVault Jul. 6 at 2:44 PM

$BVS 12.5 Call 7/17 at 0.25

0 · Reply

StockpeakHQ_1 Jul. 6 at 2:43 PM

$BVS 12.5 Call 7/17 at 0.25

0 · Reply

Blockwave1 Jul. 6 at 2:43 PM

Gamma Squeeze🌊 $BVS 12.5 Call 7/17 at 0.25

0 · Reply

LUXtrades0 Jul. 6 at 2:43 PM

$BVS 12.5 Call 7/17 at 0.25 🚨

0 · Reply

Blockwave1 Jul. 6 at 2:42 PM

$BVS 12.5 Call 7/17 at 0.25🌊

0 · Reply

StockScanners Jul. 4 at 5:08 PM

$BVS keep watch if this holds above 10.37

0 · Reply

Tradebub Jul. 2 at 8:16 PM

$BVS

0 · Reply

WhaleTracker_ Jun. 29 at 5:25 PM

$BVS is a textbook high-risk, high-reward setup. Price is currently trending above all major moving averages and looking primed for a massive breakout. On the momentum front, the daily MACD is also right on the verge of a bullish green flip. The technical target to the top of the wedge sits at a potential +103% gain. Keeping a very close eye on the volume here.

0 · Reply

Valuebuilder Jun. 24 at 8:33 AM

$BVS Crazy to see this stock in the single digits .It should be a $20 dollar stock as they have so many good products,great distribution and the ability to add more revenue without dramatically increasing cost.At some point this is going to get the attention of 2-3 funds and then it will fly as there is a lot of value here

0 · Reply

gazza01 Jun. 20 at 1:00 AM

$BVS This is the definitive proof that stem cell injections don't work for knee OA. This trial failure is good news for BVS. https://stocksdownunder.com/cynata-therapeutics-asxcyp/

0 · Reply

Market Cap	1.01B
Revenue (ttm)	568.09M
Net Income (ttm)	22.73M
EPS (ttm)	N/A
PE Ratio	15.84
Forward PE	15.13
Profit Margin	4.00%
Debt to Equity Ratio	1.16

Volume	530,100
Avg Vol	694,294
Day's Range	N/A - N/A
Shares Out	83.54M
Stochastic %K	73%
Beta	0.65
Analysts	Strong Sell
Price Target	$14.80